CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on discovering new drugs from non-actinomycete bacteria to combat drug resistance in treating diseases. It involves isolating novel bacterial strains and testing their compounds against various pathogens, aiming to diversify the sources of therapeutic agents.
The majority of compounds used to treat diseases come from a single group of organisms, the actinomycetes.
This over-reliance on a single organism to produce the worlds drugs is a major problem for the development of compounds with alternative modes of action which can overcome and delay the onset of drug resistance.
To address this problem we will form an international multi-disciplinary group of experts to bioprospect for biologically active natural products.
The central aim of this programme…
JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Vietnam, HANOI
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Thailand, Bangkok
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Bath
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Exeter
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
